| Title: |
Molecular profile and targeted therapies for ovarian clear cell ovarian cancer |
| Authors: |
Sachdeva, Manavi; Tan, David S. P. |
| Contributors: |
national medical research council; Pangestu Family Foundation Gynaecological Cancer Research Fund |
| Source: |
Therapeutic Advances in Medical Oncology ; volume 18 ; ISSN 1758-8359 1758-8359 |
| Publisher Information: |
SAGE Publications |
| Publication Year: |
2026 |
| Description: |
Ovarian clear cell carcinoma (OCCC) is a distinct epithelial ovarian cancer subtype with unique molecular features, and a notable resistance to conventional platinum-based chemotherapy in advanced disease. Key molecular hallmarks include frequent ARID1A loss and PIK3CA activation, which often co-occur and contribute to early tumorigenesis. Emerging targeted therapies—including anti-angiogenic agents, immune checkpoint inhibitors, ATR and PI3K pathway inhibitors, and antibody-drug conjugates—demonstrate promising activity, particularly in molecularly defined subgroups, though most evidence to date remains largely limited to early-phase trials. Given its rarity, chemoresistance, and underrepresentation in large trials, OCCC requires histology-specific therapeutic strategies informed by molecular profiling. Ongoing research into biomarker-driven therapies and combination regimens holds the potential to transform outcomes for this challenging ovarian cancer subtype. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1177/17588359261425693 |
| Availability: |
https://doi.org/10.1177/17588359261425693; https://journals.sagepub.com/doi/pdf/10.1177/17588359261425693; https://journals.sagepub.com/doi/full-xml/10.1177/17588359261425693 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ ; https://journals.sagepub.com/page/policies/text-and-data-mining-license |
| Accession Number: |
edsbas.7F0B3757 |
| Database: |
BASE |